This high performance is similar to the performance of CT PEER in differentiating chRCC from oncocytoma, with previously reported sensitivity of 93.2%, specificity of 87.5%, PPV of 91.1% and NPV of 90.3% regardless of CD117 status10 and accuracy up to 100% when applied to oncocytic tumours with known CD117 + status.9 This evidence concerns the gene KIT and oncocytic adenoma.